General Information of Drug (ID: DMFR23C)

Drug Name
1,2,3-triazole derivative 2 Drug Info
Synonyms PMID26161824-Compound-91
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Patented [1]
Cross-matching ID
PubChem CID
44571565
TTD Drug ID
DMFR23C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
Orlistat DMRJSP8 Obesity 5B81 Approved [4]
SR141716A DMCO5JZ Obesity 5B81 Approved [5]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [6]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [7]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [8]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [9]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [10]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [1]

References

1 A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116.
2 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
5 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
6 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 Company report (Gwpharm)
9 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
10 Clinical pipeline report, company report or official report of Bird Rock Bio.
11 Clinical pipeline report, company report or official report of Affimed Therapeutics.